F-Prime Capital

F-Prime Capital Research Investment Thesis F-Prime Capital is a global venture capital firm with a distinctive heritage spanning over 50 years, emerging from Fidelity Investments' venture capital division (founded in 1969 as Fidelity Ventures). The firm operates as an independent subsidiary of Fidelity with no outside investors, managing $5.3 billion in assets under management. F-Prime's core thesis centers on partnering with visionary founders to turn bold ambitions into world-changing breakthroughs across healthcare and technology. F-Prime employs a distinctive "technical-risk-yes, regulatory-risk-no" filter that avoids heavy regulatory categories in favor of clear FDA pathways (e.g., rare diseases and gene therapy over broad-spectrum antibiotics). The firm has created over 30 companies from scratch and built a global portfolio of 370+ companies across the Americas, Europe, and Asia. This foundation enables F-Prime to provide not just capital but operational expertise, connecting founders with Fidelity's resources and its sister fund Eight Roads to create one of the broadest cross-border VC footprints globally. Sector and Stage Focus F-Prime invests across four primary sectors: Life Sciences: Therapeutics, medtech, and biotech-focused investments. The firm creates breakthrough companies in rare diseases, gene therapy, cell therapy, and innovative diagnostics. Notable examples include companies acquired by major pharma (Semma Therapeutics by Vertex, FoldRx by Pfizer) and public companies like Beam Therapeutics (NASDAQ: BEAM), Denali Therapeutics (NASDAQ: DNLI), and Ultragenyx Pharmaceuticals (NASDAQ: RARE). Technology: Early-stage investments in enterprise software, fintech, frontier tech, and crypto. The team focuses on companies creating new infrastructure and category-defining platforms. Notable exits include Toast (NYSE: TOST), Flywire (NASDAQ: FLWY), and companies acquired by major tech firms (Kensho by S&P Global, Plaid acquisitions, Cloudant by IBM). Healthtech + Services: Digital health companies transforming patient care delivery and healthcare services. Investments span telehealth, patient engagement, data interoperability, and health management platforms. Crypto: Select investments in blockchain infrastructure and digital asset services, though with the same regulatory-risk-averse filter. Investment Approach: Stage-Agnostic While F-Prime is "early-stage investors by choice," the firm maintains flexibility to back exceptional teams at any stage. The team has demonstrated capacity across pre-seed through Series B and beyond, with the ability to lead or co-lead rounds. This stage flexibility, combined with deep operational expertise and access to Fidelity's resources, positions the firm uniquely among early-stage investors. Key Team Members and Expertise Stephen Knight, MD - President & Senior Managing Partner (since 2003). Over 30 years in pharma and biotech. Board member of numerous portfolio companies including Atalanta Therapeutics, Leyden Labs, Xaira Therapeutics. Deep life sciences expertise with MD from Yale and MBA from Yale School of Organization and Management. David Jegen - Managing Partner, Tech Fund. Leads fintech and enterprise software investments. Notable exits: Flywire (NASDAQ: FLWY), Toast (NYSE: TOST), plus companies acquired by S&P Global, BlackRock, Plaid, and others. Co-founder of Fintech Sandbox nonprofit supporting 200+ startups. Sanjay Aggarwal - Venture Partner. Focuses on physical AI and robotics. Notable investments: Seyond (IPO on HKEX), acquisitions by Vista Equity and Global Payments. Author of "2025 State of Robotics Report." Harlan Krumholz, MD - Venture Partner (joined August 2020). Focused on transformative approaches to healthcare delivery improvement. Additional experienced partners across life sciences, technology, and operations with deep domain expertise from Fidelity, consulting, and operating backgrounds. Recent Activity and Fund Status F-Prime has been actively deploying from multiple funds: Recent Investments (2025-2026): January 2026: Tenpoint Therapeutics (Drug Discovery) Alfred and additional 2026 investments across healthcare and technology October 2025: Robotics on the Rise report published, indicating continued robotics/AI focus Ongoing fintech index tracking 54 venture-backed companies with recent exits Fund Status: Actively deploying with no external investors, allowing for long-term patient capital deployment. The firm maintains reserves for pro-rata follow-on investments. Geographic Presence and Reach Three primary offices: Cambridge, MA (HQ): 1 Main St, 13th Floor - Life sciences hub and primary operational center San Francisco, CA: 140 New Montgomery Street - West Coast tech investments London, UK: 33 Foley Street - European investments and Eight Roads partnership coordination The tri-location setup enables syndication across US, Europe, and Asia-Pacific with selective focus on Japan, South Korea, and India. Check Size and Lead Tendency Based on portfolio analysis: Pre-Seed to Seed: $250K - $3M typical range Series A: $5M - $15M+ typical range Later stage: Flexible based on exceptional opportunities Lead Tendency: Leads rounds in early stage (Seed and Series A), comfortable co-leading and participating in later stages. The firm's operational expertise and founder relationships make them attractive as lead investors, particularly in healthcare and fintech. Portfolio Depth and Historical Exits Public Companies: 51 IPOs across portfolio, including major healthcare exits: Beam Therapeutics (NASDAQ: BEAM) - CRISPR base editing Denali Therapeutics (NASDAQ: DNLI) - Neurodegenerative diseases Ultragenyx Pharmaceuticals (NASDAQ: RARE) - Rare diseases Toast (NYSE: TOST) - Restaurant SaaS Flywire (NASDAQ: FLWY) - Global payments Ironwood Pharmaceuticals (NASDAQ: IRWD) - GI diseases Insmed (NASDAQ: INSM) - Rare respiratory/inflammatory diseases Recent Acquisitions: Semma Therapeutics (Vertex), Kensho (S&P Global), FutureAdvisor (BlackRock), Plaid acquisitions, and numerous others indicating consistent ability to generate value. Decision Process and Investment Philosophy Structure: Partnership-based with sector-specific teams. Life sciences team led by experienced MDs and scientists; tech team led by experienced operators and entrepreneurs. Timeline: Typically 1-4 weeks for initial decision given deep expertise in portfolio areas. Due diligence driven by operational and market understanding, not just financial metrics. Warm Introductions: Expected but not strictly required if strong founder-investor fit evident. Involvement: Board seat standard for seed/Series A leads; observer/advisor roles for participation rounds. Competitive Advantages Fidelity Heritage: Access to Fidelity's resources, data, institutional relationships, and patient capital without external pressure Portfolio-Building Capability: 50+ years of experience creating companies from scratch, not just backing existing ones Operational Network: Scientific advisors, board members, and operators across portfolio can advise portfolio companies Eight Roads Partnership: Enables global syndication across regions Stage-Agnostic Approach: Ability to support companies across growth trajectory Risk Filter: Disciplined approach to regulatory and technical risk avoidance Founder Preferences F-Prime backs: Visionary founders with deep domain expertise (especially in biotech, medtech, and fintech) Technical teams with prior exits or operating experience Category creators rather than followers Teams addressing clear market pain points with regulatory pathways defined (in healthcare) Exceptional operators who understand their industry at scale The firm avoids founders without domain expertise or unclear paths to major outcomes.